NCT06245824 2024-02-07Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer TrialCancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 4 Not yet recruiting51 enrolled